Introduction Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) may trigger autoimmune disease (AD) through initial innate immune activation with subsequent …
JK Park, EB Lee, KL Winthrop - Annals of the rheumatic diseases, 2024 - ard.bmj.com
Messenger RNA (mRNA) vaccines as a novel vaccine platform offer new tools to effectively combat both emerging and existing pathogens which were previously not possible. The …
PA Jarrot, A Mirouse, S Ottaviani, S Cadiou… - Human Vaccines & …, 2024 - Taylor & Francis
We conducted a national in-depth analysis including pharmacovigilance reports and clinical study to assess the reporting rate (RR) and to determine the clinical profile of polymyalgia …
Objectives: To compare the impact of COVID-19 on clinical status and psychological condition in patients with immune-mediated rheumatic diseases (IMRD) infected by SARS …
As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evolves, infection management in vulnerable populations requires formalized guidance. Although low …
C Baimukhamedov, G Veklenko… - Modern Rheumatology …, 2024 - academic.oup.com
Dear Editor, We read with great interest one of the latest case report in your journal on arthritis after vaccination against the severe acute respiratory syndrome coronavirus 2 …
Abstract The coronavirus disease 2019 (COVID-19) pandemic cost 7–8 million deaths worldwide, creating an unprecedented health and economic crisis. Affecting 700 million …
X Ma, L Xiao, J Wu, G Xu, J Lin… - Rheumatology & …, 2024 - Wiley Online Library
Background Polymyalgia rheumatica (PMR) is an inflammatory disease that affects the older adult population. The aim of this study was to investigate the risk and prognosis associated …
K Rose, C Iking-Konert - Die Innere Medizin, 2024 - Springer
Vaskulitiden, die im Rahmen anderer zugrunde liegender Erkrankungen auftreten, werden als sekundäre Vaskulitiden bezeichnet. In der breiten Differenzialdiagnostik der Vaskulitiden …